Chimerix
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 72
- Market Cap
- $88M
- Introduction
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 450
- Registration Number
- NCT05580562
- Locations
- π―π΅
National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
π―π΅Kyoto University Hospital, Kyoto, Japan
πΈπ¬National Cancer Centre, Singapore, Singapore
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 25
- Registration Number
- NCT05391724
- Locations
- πΊπΈ
DaVita Clinical Research, Minneapolis, Minnesota, United States
πΊπΈElite Research, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
- Conditions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- Chimerix
- Registration Number
- NCT05392374
- Locations
- πΊπΈ
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
πΊπΈAlbany Medical Center, Albany, New York, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Chimerix
- Registration Number
- NCT04617002
- Locations
- πΊπΈ
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
πΊπΈProvidence Saint John's Health Center, Santa Monica, California, United States
πΊπΈAlbany Medical Center, Albany, New York, United States
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 9
- Registration Number
- NCT04571645
- Locations
- πΊπΈ
East Carolina University Vidant Medical Center, Greenville, North Carolina, United States
πΊπΈSpartanburg Medical Gibbs Cancer Center, Spartanburg, South Carolina, United States
πΊπΈBaylor, Dallas, Texas, United States
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 102
- Registration Number
- NCT04541082
- Locations
- πΊπΈ
National Institutes of Health, Bethesda, Maryland, United States
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
- Conditions
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 27
- Registration Number
- NCT04389840
- Locations
- πΊπΈ
Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States
πΊπΈWilliam Beaumont Hospital, Royal Oak, Michigan, United States
πΊπΈAugusta University, Augusta, Georgia, United States
Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients
- Conditions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 216
- Registration Number
- NCT04285788
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Chimerix
- Registration Number
- NCT04268966
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Chimerix
- Registration Number
- NCT03532035
- Locations
- πΊπΈ
Brigham and Womens Hospital, Boston, Massachusetts, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
πΊπΈUniversity of Chigago, Chicago, Illinois, United States